市場調查報告書

液態切片的全球市場 - 各生物標記 (CTC,ct-DNA,精囊)、癌症的各類型、各產品 (檢查裝置,試劑)、各地區、各國:市場機會及未來預測

Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)

出版商 Azoth Analytics 商品編碼 915107
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
液態切片的全球市場 - 各生物標記 (CTC,ct-DNA,精囊)、癌症的各類型、各產品 (檢查裝置,試劑)、各地區、各國:市場機會及未來預測 Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)
出版日期: 2019年10月31日內容資訊: 英文 200 Pages
簡介

本報告提供全球液態切片 (液態生物檢體) 市場相關分析,產品的概要和市場基本結構,相關疾病的概要,主要的推動及阻礙市場要素,市場規模趨勢預測 (過去5年、今後6年份),各生物標記、癌症的各類型、各產品詳細趨勢,各地區、主要國家的市場結構、趨勢,主要企業的簡介、市場佔有率等調查。

第1章 分析方法

第2章 摘要整理

第3章 策略建議

第4章 液態切片市場:產品概要

第5章 全球液態切片市場:成長率與其預測 (總計8年份)

第6章 全球液態切片市場:各領域分析

  • 市場規模、佔有率:癌症的各類型
    • 肺癌症
    • 乳癌
    • 大腸癌症
    • 前列腺癌症
    • 其他
      • 市場規模 (以金額為準,總計8年份)
  • 市場向心力:癌症的各類型
  • 市場規模、佔有率:各循環生物標記
    • CTC (血中循環腫瘤細胞)
    • ct-DNA (循環腫瘤DNA)
    • 精囊
  • 市場向心力:各循環生物標記
  • 市場規模、佔有率:各產品種類
    • 試劑
    • 檢查裝置

第7章 全球液態切片市場:各地區分析

  • 各地區市場佔有率
  • 北美市場:成長率與其預測
    • 以金額為準 (總計8年份)
    • 癌症的各類型 (總計8年份)
    • 各循環生物標記 (總計8年份)
    • 各產品種類 (總計8年份)
  • 北美市場:各國分析 (美國)
  • 歐洲市場:成長率與其預測
  • 歐洲市場:各國分析 (德國,法國)
  • 亞太地區市場:成長率與其預測
  • 亞太地區市場:各國分析 (日本)
  • 其他的國家 (RoW)的市場:成長率與其預測

第8章 全球液態切片市場:競爭環境

  • 大企業的市場佔有率
  • 投資,事業聯盟
  • 產品分析

第9章 全球液態切片市場:市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場趨勢

第10章 波特的五力分析

第11章 SWOT分析

第12章 政策、法規環境

第13章 企業簡介

  • Guardant Health
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Qiagen
目錄

Executive Summary

According to Azoth Analytics research report, the Liquid Biopsy was valued at USD 899.55 million for the year 2018.

Over the recent years, Liquid Biopsy has been witnessing considerable growth on the back of growing focus on immunotherapy to cure cancer and shifting trend towards precision medicine along with high per capita healthcare expenditure and rapid adoption of novel diagnostic test by oncologist. Further, rising awareness for the early detection of cancer and sharp rise in its incidences have contributed to the growth rate of Liquid Biopsy Market.

Among the Circulating Biomarker, Ct- DNA is the most used biomarker for the diagnosis in pre and post cancerous stage, as it provides more comprehensive overview of the tumor genomic status. Ongoing research and clinical trials suggest that exosomes and nucleosomes, will provide more efficient diagnostic results and hence market will be growing in the forecast period.

In the forecast period, continuous research and development by private manufacturers, government organizations and designated government labs along with growing number of clinical trials in liquid biopsy is anticipated to provide momentum to the market growth. However, generation of revenue from the liquid biopsy is dependent upon the interest of third party payers, hindering the market growth.

Scope of the Report

Global Liquid Biopsy Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments

Regional Liquid Biopsy Markets - North America, Europe, APAC, ROW (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments

Country Analysis - U.S., Germany, France, Japan (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments

Company Analysis - Roche Diagnostics, Thermo Fisher Scientific, Guardant Health, Qiagen.

Other Report Highlights

  • Competitive Landscape - Sales, Segments, Market Share, Business Strategies
  • Investment and Partnerships
  • Product Analysis
  • Market Dynamics - Drivers and Restraints.
  • Market Trends
  • Porter Five Forces Analysis.
  • SWOT Analysis.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Liquid Biopsy Market: Product Outlook

5. Global Liquid Biopsy Market: Growth and Forecast (2017-2024)

6. Global Liquid Biopsy Market: Segment Analysis

  • 6.1 Global Liquid Biopsy Market Size, By Cancer Type: Breakdown (%)
  • 6.2 Global Lung Cancer Liquid Biopsy Market, By Value (2017-2024)
  • 6.3 Global Breast Cancer Liquid Biopsy Market, By Value (2017-2024)
  • 6.4 Global Colorectal Cancer Liquid Biopsy Market, By Value (2017-2024)
  • 6.5 Global Prostate Cancer Liquid Biopsy Market, By Value (2017-2024)
  • 6.6 Global Others Liquid Biopsy Market, By Value (2017-2024)
  • 6.7 Market attractiveness of Global Liquid Biopsy Market- By Cancer Type
  • 6.8 Global Liquid Biopsy Market Size, By Circulating Biomarker: Breakdown (%)
  • 6.9 Global CTC Liquid Biopsy Market, By Value (2017-2024)
  • 6.10 Global ct-DNA Liquid Biopsy Market, By Value (2017-2024)
  • 6.11 Global Vesicle Liquid Biopsy Market, By Value (2017-2024)
  • 6.12 Market attractiveness of Global Liquid Biopsy Market- By Circulating Biomarker
  • 6.13 Global Liquid Biopsy Market Size, By Product Type: Breakdown (%)
  • 6.14 Global Reagent Liquid Biopsy Market, By Value (2017-2024)
  • 6.15 Global Instrument Liquid Biopsy Market, By Value (2017-2024)

7. Global Liquid Biopsy Market: Regional Analysis

  • 7.1 Global Liquid Biopsy Market Size, By Region : Breakdown (%)
    • 7.1.1 Global Liquid Biopsy Market Size, By Region, 2024 (%)
  • 7.2 North America Liquid Biopsy Market: Growth and Forecast
    • 7.2.1 By Value (2017-2024)
    • 7.2.2 By Cancer Type, By Value (2017-2024)
    • 7.2.3 By Circulating Biomarker, By Value (2017-2024)
    • 7.2.4 By Product Type, By Value (2017-2024)
  • 7.3 North America Liquid Biopsy Market: Country Analysis (U.S)
    • 7.3.1 U.S Liquid Biopsy Market, By Value (2017-2024)
    • 7.3.2 U.S Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
    • 7.3.3 U.S Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
    • 7.3.4 U.S Liquid Biopsy Market, By Product Type, By Value (2017-2024)
  • 7.4 Europe Liquid Biopsy Market: Growth and Forecast
    • 7.4.1 By Value (2017-2024)
    • 7.4.2 By Cancer Type, By Value (2017-2024)
    • 7.4.3 By Circulating Biomarker, By Value (2017-2024)
    • 7.4.4 By Product Type, By Value (2017-2024)
  • 7.5 Europe Liquid Biopsy Market: Country Analysis (Germany, France)
    • 7.5.1 Germany Liquid Biopsy Market, By Value (2017-2024)
    • 7.5.2 Germany Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
    • 7.5.3 Germany Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
    • 7.5.4 Germany Liquid Biopsy Market, By Product Type, By Value (2017-2024)
    • 7.5.5 France Liquid Biopsy Market, By Value (2017-2024)
    • 7.5.6 France Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
    • 7.5.7 France Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
    • 7.5.8 France Liquid Biopsy Market, By Product Type, By Value (2017-2024)
  • 7.6 APAC Liquid Biopsy Market: Growth and Forecast
    • 7.6.1 By Value (2017-2024)
    • 7.6.2 By Cancer Type, By Value (2017-2024)
    • 7.6.3 By Circulating Biomarker, By Value (2017-2024)
    • 7.6.4 By Product Type, By Value (2017-2024)
  • 7.7 APAC Liquid Biopsy Market: Country Analysis (Japan)
    • 7.7.1 Japan Liquid Biopsy Market, By Value (2017-2024)
    • 7.7.2 Japan Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
    • 7.7.3 Japan Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
    • 7.7.4 Japan Liquid Biopsy Market, By Product Type, By Value (2017-2024)
  • 7.8 ROW Liquid Biopsy Market: Growth and Forecast
    • 7.8.1 By Value (2017-2024)
    • 7.8.2 By Cancer Type, By Value (2017-2024)
    • 7.8.3 By Circulating Biomarker, By Value (2017-2024)
    • 7.8.4 By Product Type, By Value (2017-2024)

8. Global Liquid Biopsy Market: Competitive Landscape

  • 8.1 Market share of Leading Global Companies
  • 8.2 Global Liquid Biopsy Market : Investments and Partnerships
  • 8.3 Global Liquid Biopsy Market: Product Analysis

9. Global Liquid Biopsy Market Dynamics

  • 9.1 Global Liquid Biopsy Market Drivers
    • 9.1.1 Rising incidence of cancer
    • 9.1.2 Growing focus on immunotherapy to cure cancer
    • 9.1.3 Growing government expenditure in cancer research
  • 9.2 Global Liquid Biopsy Market Restraints
    • 9.2.1 Technology is dependent upon the interest shown by third party payers
  • 9.3 Global Liquid Biopsy Market Trend
    • 9.3.1 Adoption of precision medicine for curing cancer
    • 9.3.2 Early detection of cancer

10. Porter's Five Forces Analysis

11. SWOT Analysis

12. Policy and Regulatory Landscape

13. Company Profiles

  • 13.1 Guardant Health
  • 13.2 Roche Diagnostics
  • 13.3 Thermo Fisher Scientific
  • 13.4 Qiagen

List of Figures

  • Figure 1:Global Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
  • Figure 2:Potential opportunities of liquid biopsy across cancer continuum care
  • Figure 3:Key factors driving of change in the global oncology market
  • Figure 4:Value based payment models for cancer care
  • Figure 5:Biotechnology Research and Development Services Cost Index, In 2018
  • Figure 6:Biopharmaceutical therapy selection market opportunity
  • Figure 7:Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000)
  • Figure 8:Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)
  • Figure 9:Global Prevalence of Different Type of Cancer, 2017 (In Thousands)
  • Figure 10:Global Prevalence of Prostate Cancer (2013-2017, Thousands)
  • Figure 11:Prevalence and Epidemiology of Cancer Worldwide
  • Figure 12:5 Year Survival Rate, Breast and Colorectal Cancer
  • Figure 13:Global Liquid Biopsy Market Size, By Type, 2024 (In %)
  • Figure 14:Global Lung Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 15:Global Breast Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 16:Global Colorectal Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 17:Global Prostate Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 18:Global Other Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 19:Market Opportunity Chart of Global Liquid Biopsy Market - By Cancer Type, By Value (Year - 2024)
  • Figure 20:Global Liquid Biopsy Market Size, By Type, 2024 (In %)
  • Figure 21:Global CTC Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 22:Global ct-DNA Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 23:Global Vesicles Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 24:Market Opportunity Chart of Global Liquid Biopsy Market - By Circulating Biomarker, By Value (Year - 2024)
  • Figure 25:Global Liquid Biopsy Market Size, By Type, 2024 (In %)
  • Figure 26:Global Reagent Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 27:Global Instrument Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
  • Figure 28:Market Opportunity Chart of Global Liquid Biopsy Market - By Product Type, By Value (Year - 2024)
  • Figure 29:Global Healthcare Landscape, By Select Region
  • Figure 30:Global Liquid Biopsy Market Size, By Region, 2024 (%)
  • Figure 31:North America Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
  • Figure 32:North America GDP, 2012-2017 (USD Trillion)
  • Figure 33: North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 34:Prevalence of Different Type of Cancer in North America in year 2016 & 2017 ( In Hundreds)
  • Figure 35:North America, Cancer Incidence (In Millions)
  • Figure 36:North America, Cancer Incidence, 2019 (In %)
  • Figure 37:North America, Cancer Incidence, 2019 (In %)
  • Figure 38:North America GDP, 2012-2017 (USD Trillion)
  • Figure 39:North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 40:North America Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 41:North America Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 42:North America Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 43:USA Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
  • Figure 44:Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %)
  • Figure 45:Leading Sites of New Cancer Cases in the United States amongst Females, 2018 (In %)
  • Figure 46:Estimated New Cases of Cancer in the United States, By Type 2018 (In %)
  • Figure 47:Estimated New Cases of Cancer in the United States, 2014-2018 (In Thousands)
  • Figure 48:Estimated New Cases of Cancer in the United States, By State, 2018
  • Figure 49: Percentage of adults aged 18-64 with insurance coverage in United States, By Poverty status, In 2018
  • Figure 50:Percentage of individuals with insurance coverage in United States, By Age Group, In 2018
  • Figure 51:Medical and Healthcare Research & Development Spending, 2014-2017 (In USD Million)
  • Figure 52:Research and Development Expenditure of total U.S. Pharmaceutical Industry, 2013-2017, (USD Billion)
  • Figure 53:US Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 54:US Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 55:US Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 56:Europe Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
  • Figure 57:Europe, Cancer Incidence, 2019E-2035F (In Millions)
  • Figure 58:Europe, Cancer Incidence, By Type, 2019E
  • Figure 59:Prevalence of Different Type of Cancer in Western Europe in year 2016 & 2017 ( In Thousands)
  • Figure 60:Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 61:GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
  • Figure 62:Europe Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 63:Europe Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 64:Europe Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 65: Germany Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
  • Figure 66:Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
  • Figure 67:Prevalence of Different Type of Cancer in Germany in year 2016 & 2017 ( In Hundreds)
  • Figure 68:German Pharmaceutical companies expenditure on R&D, In Million Euros
  • Figure 69:Germany, Population ages 65 and above, 2012-2018 (% total)
  • Figure 70:Germany Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 71:Germany Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 72:Germany Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 73:France Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
  • Figure 74:France, Number of Biotech Companies, By Type, 2017
  • Figure 75:France, Prevalence of Cancer, 2018, (% of total)
  • Figure 76:Healthcare expenditure in France ( as a % of GDP)
  • Figure 77:Healthcare spending pattern in France, In 2016 & 2050, In USD $
  • Figure 78:France Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 79:France Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 80:France Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 81: APAC Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
  • Figure 82:Estimated number of deaths from prostate cancer in 2012 and 2030
  • Figure 83:World health expenditure as % of GDP
  • Figure 84:Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
  • Figure 85:Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
  • Figure 86:APAC, GDP, By Select Country, 2017 (In USD Trillion)
  • Figure 87:APAC Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 88:APAC Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 89:APAC Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 90:Japan Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
  • Figure 91:Japan, Cancer Prevalence, By Type, (2018)
  • Figure 92:Proportional mortality in Japan, In 2018
  • Figure 93:Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 94:Japan, Population ages 65 and above, 2012-2018 (% of total)
  • Figure 95:Japan Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 96:Japan Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 97: Japan Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 98:ROW Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
  • Figure 99:Middle East and North Africa, GDP, 2012-2017 (In USD Trillion)
  • Figure 100:Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %)
  • Figure 101:Prevalence of Different Type of Cancer in Middle East and North Africa in year 2016 & 2017 ( In Hundreds)
  • Figure 102:Prevalence of Different Type of Cancer in Brazil in year 2016 & 2017 ( In Hundreds)
  • Figure 103:Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 104:Population ages 60 and above, By Select Country, 2050 (% of total)
  • Figure 105:ROW Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
  • Figure 106:ROW Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
  • Figure 107:ROW Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
  • Figure 108:Global Liquid Biopsy Market Share, By Select Company, 2018 (In %)
  • Figure 109:Guardant Health, Sales Revenue, 2016-2018 (USD Million)
  • Figure 110:Guardant Health, Sales Revenue, By Segment, In 2018 (USD Million)
  • Figure 111:Roche Diagnostics, Sales Revenue, 2014-2018 (USD Million)
  • Figure 112:Roche Diagnostics, Sales Revenue, By Diagnostic Segment, In 2018 (USD Million)
  • Figure 113: Roche Diagnostics, Molecular Diagnostics Sales Revenue, By Geographical Segment, In 2018 (USD Million)
  • Figure 114:Thermo Fisher Scientific, Sales Revenue, 2014-2018 (USD Million)
  • Figure 115:Thermo Fisher Scientific, Sales Revenue, By Business Segment, In 2018 (USD Million)
  • Figure 116:Thermo Fisher Scientific, Sales Revenue, By Geographical Segment, In 2018 (USD Million)
  • Figure 117:Qiagen, Sales Revenue, 2014-2018 (USD Million)
  • Figure 118:Qiagen, Sales Revenue, By Business Segment, In 2018 (USD Million)
  • Figure 119:Qiagen, Sales Revenue, By Geographical Segment, In 2018 (USD Million)

List of Tables

  • Table A:Estimated Numbers of US Cancer Survivors (As of January 1, 2016)
  • Table B:Estimated Numbers of US Cancer Survivors (As of January 1, 2026F)
  • Table C:Germany, Healthcare Related Statistics, 2017
  • Table D:Recent Investments and Partnerships in Liquid Biopsy Market
  • Table E:Liquid Biopsy assays using c- tumor cells, as yet
  • Table F:Liquid Biopsy assays using circulating free DNA, as yet
  • Table G:Ongoing clinical trials in ct- DNA liquid biopsy
  • Table H:Ongoing clinical trials in CTC liquid biopsy